ZELSUVMI™ (berdazimer topical gel, 10.3%)
Molluscum Contagiosum
ApprovedCommercial
Key Facts
About Pelthos Therapeutics
Pelthos Therapeutics is a San Diego-based biopharmaceutical company with a mission to commercialize innovative therapies for patients with unmet dermatological needs. Its core achievement is the FDA approval of ZELSUVMI™ for molluscum contagiosum, complemented by a strategic portfolio of acquired, late-stage topical products. The company's strategy leverages a dual approach: a commercial engine for launching acquired assets and a proprietary NITRICIL™ nitric oxide platform for future internal development, aiming to build a sustainable, revenue-generating dermatology franchise.
View full company profileTherapeutic Areas
Other Molluscum Contagiosum Drugs
| Drug | Company | Phase |
|---|---|---|
| Zabalafin Hydrogel (AB-101a) | Alphyn Biologics | Phase 2 |
| YCANTH (Cantharidin) | Torii Pharmaceutical | Approved |
| Exploratory Asset | Veradermics | Discovery |
| YCANTH (VP-102) | Verrica Pharmaceuticals | Approved |